Genmab stock keeps focus on pipeline after strong nine-month growth

Published on 11/11/2026 at 02:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genmab stock remains tied to a broad late-stage pipeline after nine-month revenue rose 22%. The company kept its full-year outlook unchanged.

Pipeline Expansion Supports Guidance

Genmab maintained its 2026 financial outlook after reporting nine-month revenue growth.
EPKINLY and TEPKINLY sales increased as the company expanded approvals and late-stage development programs.
New phase 3 studies broadened petosemtamab's potential reach into colorectal cancer.

Genmab, DK0010272202, Illustration mit AI erstellt.

Genmab reported revenue of USD 3.238 billion for the first nine months of 2026, up 22% from the same period a year earlier. The Danish biotechnology company maintained its full-year financial guidance while pointing to further regulatory and commercial milestones for its late-stage portfolio.

The results were announced on November 5 in Genmab's nine-month results release. Royalty revenue reached USD 2.699 billion, while global EPKINLY and TEPKINLY sales rose 47% to USD 491 million.

Costs Rise With Pipeline Investment

Operating expenses increased 35% to USD 2.018 billion, reflecting investment in the product pipeline and preparations for anticipated launches. The figure included USD 87 million in acquisition and integration charges related to Merus and USD 35 million in amortization of acquired intangible assets.

Operating profit declined to USD 986 million from USD 1.007 billion. Adjusted operating profit, which excludes the acquisition and integration charges and amortization, increased to USD 1.108 billion from USD 1.016 billion.

Clinical Milestones Broaden Reach

Genmab said epcoritamab was approved in Europe as TEPKINLY and in Japan as EPKINLY, in combination with R2, for adults with relapsed or refractory follicular lymphoma. The company also initiated two phase 3 trials of petosemtamab in first- and second-line colorectal cancer.

Post-quarter developments included positive topline results for epcoritamab in newly diagnosed diffuse large B-cell lymphoma, Rina-S in platinum-resistant ovarian cancer and petosemtamab combined with pembrolizumab in first-line recurrent or metastatic head and neck cancer. Genmab plans to engage regulators on potential next steps and described the late-stage portfolio as supporting possible launches in 2027.

Antibody Specialist Uses Partnerships

Genmab develops antibody-based therapeutics, technologies and expertise for patients and works with partners across its product portfolio, according to its investor relations site. Its disclosed programs include epcoritamab, Rina-S and petosemtamab, with collaborations involving AbbVie, Johnson & Johnson and Novartis. Genmab is therefore positioned as a specialized oncology and antibody developer alongside larger pharmaceutical partners with broader commercial footprints.